Editas Medicine, Inc.
EDITFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Editas Medicine, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 12 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 22, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| MACKENZIE FINANCIAL CORP | 2026-03-31 | 730,054 | $1.8M | SEC filing |
| Advisory Services Network, LLC | 2026-03-31 | 65 | $161 | SEC filing |
| Callan Family Office, LLC | 2026-03-31 | 14,463 | $35.7K | SEC filing |
| Federation des caisses Desjardins du Quebec | 2026-03-31 | 2,300 | $5.68K | SEC filing |
| Owl Creek Wealth Partners LLC | 2026-03-31 | 2,385 | $5.89K | SEC filing |
| BlackRock, Inc. | 2026-03-31 | 9,263,312 | $22.9M | SEC filing |
| Legal & General Group Plc | 2026-03-31 | 7,778 | $19.3K | SEC filing |
| Pinnacle Wealth Planning Services, Inc. | 2026-03-31 | 100 | $247 | SEC filing |
| SIMPLEX TRADING, LLC | 2026-03-31 | 5,981 | $14.8K | SEC filing |
| Larson Financial Group LLC | 2026-03-31 | 289 | $714 | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 145,602 | $360K | SEC filing |
| Creative Planning | 2026-03-31 | 23,084 | $57K | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 411,192 | $1.02M | SEC filing |
| Blue Trust, Inc. | 2026-03-31 | 1,600 | $3.95K | SEC filing |
| Parkside Financial Bank & Trust | 2026-03-31 | 410 | $1.02K | SEC filing |
| ISLAY CAPITAL MANAGEMENT, LLC | 2026-03-31 | 150 | $371 | SEC filing |
| Optiver Holding B.V. | 2026-03-31 | 519 | $1.28K | SEC filing |
| WELLS FARGO & COMPANY/MN | 2026-03-31 | 102,030 | $252K | SEC filing |
| ROYAL BANK OF CANADA | 2026-03-31 | 7,506 | $18K | SEC filing |
| Kera Capital Partners, Inc. | 2026-03-31 | 10,729 | $26.5K | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Editas Medicine, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-06-03 · O'Neill Gilmore Neil: Larger than 86 of the 92 other insider sales of Common Stock on file. SEC filing
- 2025-06-03 · O'Neill Gilmore Neil: Larger than 85 of the 92 other insider sales of Common Stock on file. SEC filing
- 2025-03-04 · O'Neill Gilmore Neil: Larger than 87 of the 92 other insider sales of Common Stock on file. SEC filing
- 2024-06-04 · O'Neill Gilmore Neil: Larger than 83 of the 92 other insider sales of Common Stock on file. SEC filing
- 2024-05-20 · Lucera Erick: Larger than 91 of the 92 other insider sales of Common Stock on file. SEC filing
- 2024-03-05 · O'Neill Gilmore Neil: Larger than all 92 other insider sales of Common Stock on file. SEC filing
- 2024-03-04 · Mei Baisong: Larger than 90 of the 92 other insider sales of Common Stock on file. SEC filing
- 2022-01-03 · MULLEN JAMES C: Larger than 88 of the 92 other insider sales of Common Stock on file. SEC filing
- 2021-10-18 · MULLEN JAMES C: Larger than 84 of the 92 other insider sales of Common Stock on file. SEC filing
- 2020-12-07 · Albright Charles: Larger than 89 of the 92 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-03 | O'Neill Gilmore Neil · CEO | Common Stock | S — Open market or private sale | −15,380 | 2.70 | SEC filing |
| 2026-06-03 | Burkly Linda · EVP, CHIEF SCIENTIFIC OFFICER | Common Stock | S — Open market or private sale | −731 | 2.70 | SEC filing |
| 2026-06-03 | Parison Amy · SVP, Chief Financial Officer | Common Stock | S — Open market or private sale | −464 | 2.70 | SEC filing |
| 2026-03-03 | Burkly Linda · EVP, CHIEF SCIENTIFIC OFFICER | Common Stock | S — Open market or private sale | −749 | 2.02 | SEC filing |
| 2026-03-03 | Parison Amy · SVP, Chief Financial Officer | Common Stock | S — Open market or private sale | −474 | 2.02 | SEC filing |
| 2026-03-03 | O'Neill Gilmore Neil · CEO | Common Stock | S — Open market or private sale | −5,394 | 2.02 | SEC filing |
| 2025-12-03 | Parison Amy · SVP, Chief Financial Officer | Common Stock | S — Open market or private sale | −461 | 2.15 | SEC filing |
| 2025-12-03 | Burkly Linda · EVP, CHIEF SCIENTIFIC OFFICER | Common Stock | S — Open market or private sale | −713 | 2.15 | SEC filing |
Showing 8 of 14 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-17 | Connaughton Bernadette · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +51,700 | SEC filing |
| 2026-06-17 | Hirsch Andrew · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +51,700 | SEC filing |
| 2026-06-17 | Scadden David · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +51,700 | SEC filing |
| 2026-06-17 | Hopfield Jessica · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +51,700 | SEC filing |
| 2026-06-17 | Levy Elliott M. · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +51,700 | SEC filing |
| 2026-03-12 | Burkly Linda · EVP, CHIEF SCIENTIFIC OFFICER | Stock Option (right to buy) | A — Grant, award, or other acquisition | +292,856 | SEC filing |
| 2026-03-12 | Parison Amy · SVP, Chief Financial Officer | Stock Option (right to buy) | A — Grant, award, or other acquisition | +292,856 | SEC filing |
| 2026-03-12 | O'Neill Gilmore Neil · CEO | Stock Option (right to buy) | A — Grant, award, or other acquisition | +1,015,200 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.